Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…

Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detect...

Descripción completa

Detalles Bibliográficos
Autor: Allegri, Ricardo Francisco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/169826
Acceso en línea:http://hdl.handle.net/11336/169826
Access Level:acceso abierto
Palabra clave:ALZHEIMER DISEASE
BIOMARKERS
DEMENTIA
FRONTOTEMPORAL DEMENTIA
PROTEINS
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
id AR_4e4e1b6a69131624dff160e42280d3a5
oai_identifier_str oai:ri.conicet.gov.ar:11336/169826
network_acronym_str AR
network_name_str Argentina
repository_id_str
dc.title.none.fl_str_mv Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
Passando de demencias neurodegenerativas para proteinopatias cognitivas, substituindo ''onde'' por ''0 que''…
title Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
spellingShingle Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
Allegri, Ricardo Francisco
ALZHEIMER DISEASE
BIOMARKERS
DEMENTIA
FRONTOTEMPORAL DEMENTIA
PROTEINS
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
title_short Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
title_full Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
title_fullStr Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
title_full_unstemmed Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
title_sort Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…
dc.creator.none.fl_str_mv Allegri, Ricardo Francisco
author Allegri, Ricardo Francisco
author_facet Allegri, Ricardo Francisco
author_role author
dc.subject.none.fl_str_mv ALZHEIMER DISEASE
BIOMARKERS
DEMENTIA
FRONTOTEMPORAL DEMENTIA
PROTEINS
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
topic ALZHEIMER DISEASE
BIOMARKERS
DEMENTIA
FRONTOTEMPORAL DEMENTIA
PROTEINS
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
description Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer’s disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us “where” abnormal tissue is found but not “what” molecular mechanisms are involved.
publishDate 2020
dc.date.none.fl_str_mv 2020-09-18
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/169826
Allegri, Ricardo Francisco; Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…; Academia Brasileira de Neurologia; Dementia & Neuropsychologia; 14; 3; 18-9-2020; 237-242
1980-5764
2764-4863
CONICET Digital
CONICET
url http://hdl.handle.net/11336/169826
identifier_str_mv Allegri, Ricardo Francisco; Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…; Academia Brasileira de Neurologia; Dementia & Neuropsychologia; 14; 3; 18-9-2020; 237-242
1980-5764
2764-4863
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.scielo.br/j/dn/a/ftRYYctPTnkfb9yL7cD6nXK/?lang=en
info:eu-repo/semantics/altIdentifier/doi/10.1590/1980-57642020dn14-030005
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia
publisher.none.fl_str_mv Academia Brasileira de Neurologia
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799196090187120640
spelling Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…Passando de demencias neurodegenerativas para proteinopatias cognitivas, substituindo ''onde'' por ''0 que''…Allegri, Ricardo FranciscoALZHEIMER DISEASEBIOMARKERSDEMENTIAFRONTOTEMPORAL DEMENTIAPROTEINShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer’s disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us “where” abnormal tissue is found but not “what” molecular mechanisms are involved.As demências neurodegenerativas foram descritas com base em seu fenótipo, em relação à degeneração seletiva que ocorre em um sistema neuroanatômico específico. Mais recentemente, no entanto, o termo proteinopatia foi introduzido para descrever doenças nas quais uma ou mais proteínas alteradas podem ser detectadas. As doenças neurodegenerativas podem ser produzidas por mais de uma proteína anormal e cada proteinopatia pode determinar diferentes fenótipos clínicos. Biomarcadores específicos já foram associados a certas patologias moleculares em pacientes vivos. Em 2016, uma nova classificação baseada em biomarcadores, atualmente aprovada apenas para pesquisas na doença de Alzheimer, foi introduzida. É baseado na avaliação de três biomarcadores: amiloide (A) detectado no ensaio amiloide-PET ou amiloide-beta 42 no LCR; tau (T) medida no LCR como tau fosforilada ou em imagem de tau PET; e lesão/neurodegeneração neuronal (N), detectada por T-tau total no LCR, hipometabolismo FDG PET e pela ressonância magnética. Os resultados de pesquisas clínicas usando os biomarcadores ATN no FLENI, um Instituto Neurológico de Buenos Aires, Argentina, desde 2011, contribuíram para os esforços contínuos para se afastar do conceito de demência neurodegenerativa e mover-se mais em direção às proteinopatias cognitivas. Hoje, o diagnóstico clínico da demência só pode nos dizer “onde” o tecido anormal é encontrado, mas não “quais” mecanismos moleculares estão envolvidos.Fil: Allegri, Ricardo Francisco. Universidad de la Costa; Colombia. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Instituto de Neurociencias - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Neurociencias; ArgentinaAcademia Brasileira de Neurologia2020-09-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/169826Allegri, Ricardo Francisco; Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing ''where'' by ''what''…; Academia Brasileira de Neurologia; Dementia & Neuropsychologia; 14; 3; 18-9-2020; 237-2421980-57642764-4863CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.scielo.br/j/dn/a/ftRYYctPTnkfb9yL7cD6nXK/?lang=eninfo:eu-repo/semantics/altIdentifier/doi/10.1590/1980-57642020dn14-030005info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T14:14:24Zoai:ri.conicet.gov.ar:11336/169826instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 14:14:24.439CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
score 15,812429

Similares en LA Referencia